I-Corps: Fiber Scaffold Platform For 3D Cell Culture

I-Corps：用于 3D 细胞培养的纤维支架平台

• 批准号: 2016272
• 负责人: Vladimir Reukov
• 金额: $ 5万
• 依托单位: University of Georgia Research Foundation Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2023-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2016272&HistoricalAwards=false
• 关键词: Corps; Fiber; Scaffold; Platform; 3D

The broader impact/commercial potential of this I-Corps project is in the translation of scalable three-dimensional cell culture (3DCC) technology. In 2019 the global and U.S. market sizes for 3DCC technologies were $400M and $150M, respectively, expected to grow at 15% CAGR through 2024. Recent advances in tissue engineering and regenerative medicine, cancer and stem cell research are made possible through the advent of 3DCC techniques, replacing the traditional two-dimensional cell cultures. 3DCC techniques are expected to better mimic natural tissue conditions. The proposed 3D scaffolding technology offers highly customizable scaffolds with specific cell type environments, offering high yield and scalable production of biopharmaceuticals. This will impact the drug discovery market by improving the reliability of preclinical screening and reduced animal model usage. Further, this 3DCC platform innovation will accelerate the research and commercial activities in tissue engineering, cancer and stem cell markets. This I-Corps project explores translation of improved three-dimensional cell culture (3DCC) methods. Large-scale production and isolation of cellular metabolites of pharmaceutical value, as well as rapidly growing tissue engineering applications, call for a rapid and high-yield 3DCC technique that supports the right cell phenotype with healthy cell population through a better nutrient and metabolite exchange over an extended period. Despite significant success of laboratory-scale 3DCC techniques to grow microtissues, they largely misrepresent the natural extracellular (ECM) characteristics, and lack of established high-throughput and rapid screening protocols for drug discovery are hurdles to adopt 3DCC widely in biopharmaceutical industry and research. Therefore, a better scalable 3DCC technique closely mimicking the natural ECM is urgently needed. The proposed 3D scaffolding technology enables biocompatible polymeric fibers as building blocks to recreate the cell-specific scaffold in a bottoms-up approach, mimicking the natural ECMs closely with higher cell yields. Further, these scaffolds can be optimized and scalable to specific applications.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个I-Corps项目更广泛的影响/商业潜力在于可扩展的三维细胞培养（3DCC）技术的转化。 2019年，3DCC技术的全球和美国市场规模分别为4亿美元和1.5亿美元，预计到2024年将以15%的复合年增长率增长。组织工程和再生医学，癌症和干细胞研究的最新进展是通过3DCC技术的出现，取代传统的二维细胞培养。3DCC技术有望更好地模拟天然组织条件。所提出的3D支架技术提供了具有特定细胞类型环境的高度可定制的支架，提供了生物制药的高产量和可扩展的生产。 这将通过提高临床前筛选的可靠性和减少动物模型的使用来影响药物发现市场。此外，这一3DCC平台创新将加速组织工程、癌症和干细胞市场的研究和商业活动。这个I-Corps项目探索了改进的三维细胞培养（3DCC）方法的翻译。具有药用价值的细胞代谢物的大规模生产和分离，以及快速增长的组织工程应用，需要快速和高产的3DCC技术，该技术通过在较长时间内更好的营养和代谢物交换，支持健康细胞群的正确细胞表型。 尽管实验室规模的3DCC技术在生长微组织方面取得了重大成功，但它们在很大程度上歪曲了天然细胞外（ECM）特征，并且缺乏用于药物发现的既定高通量和快速筛选方案是在生物制药工业和研究中广泛采用3DCC的障碍。因此，迫切需要一种更好的可扩展的3DCC技术，密切模仿天然ECM。所提出的3D支架技术使生物相容性聚合物纤维作为构建块，以自下而上的方法重建细胞特异性支架，以更高的细胞产量密切模仿天然ECM。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。